Spearhead Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Spearhead Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,996	Closed	-$438K	–	227
2021 Q4	$438K	Buy	1,996 +15	+0.8%	+$2.92K	0.05%	107
2021 Q3	$359K	Buy	1,981 +2	+0.1%	+$390	0.05%	134
2021 Q2	$399K	Buy	1,979 +248	+14%	+$51.9K	0.05%	142
2021 Q1	$372K	Buy	1,731 +743	+75%	+$163K	0.05%	108
2020 Q4	$234K	Buy	988 +53	+6%	+$12.2K	0.04%	163
2020 Q3	$254K	Buy	935 +66	+8%	+$18.2K	0.05%	153
2020 Q2	$252K	Buy	+869	New	+$236K	0.05%	128

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Spearhead Capital Advisors's VRTX Position: Q1 2022 in Review

Spearhead Capital Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2022, closing a stake of 1,996 shares — an estimated $438K sold.

Spearhead Capital Advisors first reported a position in VRTX in Q2 2020 and held it in 7 quarters. The position peaked at $438K in Q4 2021. 1,071 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

Spearhead Capital Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Spearhead Capital Advisors sold 1,996 Vertex Pharmaceuticals shares in Q1 2022, an estimated $438K.
Spearhead Capital Advisors first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 7 quarters.
Spearhead Capital Advisors's Vertex Pharmaceuticals position peaked at $438K in Q4 2021.
1,071 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Spearhead Capital Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.